Apremilast for psoriatic arthritis
The National Institute for Health and Care Excellence (NICE) has issued draft guidance for consultation that does not recommend apremilast for psoriatic arthritis. The consultation documents (ID682) can be accessed on NICE’s website under the guidance in development section. The closing date for comments on the draft guidance is 10 July 2015. Final guidance is expected in October 2015.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068798
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com